Equity Details
Price & Market Data
Price: $4.68
Daily Change: +$0.08 / 1.71%
Daily Range: $4.51 - $4.81
Market Cap: $233,504,528
Daily Volume: 577,980
Performance Metrics
1 Week: -5.22%
1 Month: -5.79%
3 Months: -31.20%
6 Months: -19.32%
1 Year: -32.76%
YTD: -42.93%
About Cybin D/B/A Helus Pharma (HELP)
Explore the latest financial data for Cybin D/B/A Helus Pharma (HELP). Price: 4.68, daily change: +$0.08 / 1.71%. Market cap: 233,504,528. Performance over 1-month, 6-month, and 1-year.
Company Details
Employees: 50
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Canada
Details
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
